Trial Profile
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Ipatasertib (Primary) ; Midazolam
- Indications Advanced breast cancer; Male breast cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Genentech
- 01 Dec 2021 Results assessing single- and multiple-dose pharmacokinetics (PK), CYP3A inhibition potential of ipatasertib, and effect of food on PK of ipatasertib in patients with refractory solid tumors and a dedicated food effect assessment in healthy subjects published in the Cancer Chemotherapy and Pharmacology
- 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 10 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.